PF-08634404 advanced cancer study stays recruiting in Phase 1 and Phase 2
The study tests PF-08634404 with two different anticancer combinations and tracks safety, dose-limiting toxicity, and response.
A new ClinicalTrials.gov registry observation lists Symbiotic-Lung-20 as RECRUITING, with the study published 2026-11-20T00:00:00+00:00. For people following cancer research, the practical takeaway is simple: this study is open and is testing PF-08634404 in advanced cancers, but no results are posted yet.
The study is titled “Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers.” It is in PHASE1, PHASE2 and uses a NON_RANDOMIZED design under Pfizer. The record shows two experimental parts: PF-08634404 + Sigvotatug Vedotin (Part A) and PF-08634404 + PF-08046054/SGN-PDL1V (Part B).
What the study is measuring
The primary outcomes focus first on safety. One measure is the number of participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), described as events tracked by type, frequency, severity, timing, seriousness, and relationship to study intervention. Another phase I measure is the number of participants with dose limiting toxicity (DLT).
The phase 2 outcome is Confirmed Objective Response Rate (ORR) per RECIST v1.1 by investigator. In plain terms, that asks how many participants have a confirmed complete or partial response. The time frames listed run through 90 days after the last study intervention and, for some measures, up to approximately 5 years.
Why this registry update matters now
The record does not include results, so it should be read as a status update rather than evidence that the combinations work. What it does show is that Pfizer is still advancing a trial structure that pairs PF-08634404 with different anticancer agents while keeping close watch on safety and tumor response.
The study’s estimated primary completion date is 2029-03-08. That means the most current fact available here is not an outcome, but a live recruiting status that places this trial among other cancer studies now being tracked in the active “Cancer Breakthroughs” special event.
More cancer trial coverage
Readers interested in the broader cancer-trial picture can also follow related registry observations in the same special event, including ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy and A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. Those studies are separate, but they point to the same larger theme: ongoing testing across different cancer types and treatment approaches.
This registry observation does not settle whether PF-08634404 will help in advanced cancers. It does show where the study stands today, what combinations are being tried, and which outcomes investigators will use to judge safety and activity going forward.